Lancaster, PANCT05835037Now EnrollingIRB Ready

Prediabetic State Clinical Trial in Lancaster, PA

Access cutting-edge prediabetic state treatment through this clinical trial at a research site in Lancaster. Study-provided care at no cost to qualified participants.

Sponsored by University of Maryland, Baltimore

Quick Self-Assessment

See if you qualify for this Lancaster location

Preparing your pre-screening questions…

Expert Care in Lancaster

Access prediabetic state specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related prediabetic state treatment provided free

Apply for This Lancaster Location

Check if you qualify for this prediabetic state clinical trial in Lancaster, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Lancaster

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Lancaster site if eligible
  4. 4Begin participation

About This Prediabetic State Study in Lancaster

The purpose of this investigation is to evaluate the impact of zinc supplementation on fasting glucose levels, hemoglobin A1c (HbA1c), and other indices of glucose homeostasis in individuals with prediabetes. The investigators hypothesize that prediabetic subjects receiving zinc will demonstrate a greater decrease in HbA1c and blood glucose compared to prediabetic subjects receiving placebo. Specific Aim: Conduct a prospective, double-blind randomized clinical trial comparing the effects of 12 months of zinc supplementation (zinc gluconate 30 milligram \[mg\] per day) versus placebo on glucose homeostasis. Based upon expected effect size and power calculations, and anticipating a 20% drop-out rate, the investigators will study 200 prediabetic subjects (100 per group) using a 1:1 randomization design. HbA1c, fasting plasma glucose, and other measures will be obtained at 0, 6, and 12 months and will be compared between zinc supplementation and placebo groups.

Sponsor: University of Maryland, Baltimore

Who Can Participate

Inclusion Criteria

Amish men or women who are 18 to 80 years old
Prediabetes (HgbA1c = 5.7-6.4% or fasting glucose levels 100-125 mg/dL)

Exclusion Criteria

Currently breastfeeding
History of severe gastrointestinal disorders or upper gastrointestinal surgery
Has hemochromatosis, cancer, liver disease, kidney disease, cardiovascular disease, or other coexisting malignancy
Hemoglobin \< 12.5 g/dl (male) or \< 11 g/dl (female)
Severe hypertension (blood pressure \> 160/95 mm Hg)
Has a creatinine greater than 2.0 mg/dl, aspartate aminotransferase (AST) or alanine transaminase (ALT) greater than 2 times the upper limit of normal, hematocrit (Hct) less than 32%, or thyroid-stimulating hormone (TSH) less than 0.4 or greater than 5.5 milli-international units (mIU) per liter.
At the discretion of the study physician or PI, taking medications that affect the outcomes of the study including, but not limited to, corticosteroids, anti-psychotic agents, protease inhibitors, oral contraceptives, estrogens, niacin, and some classes of antidepressants, statins, and antihypertensive medications
Zinc hypersensitivity
Use of denture adhesive containing zinc
Taking other medications or zinc-containing supplements and is unwilling or cannot safely, in the opinion of the study physician, discontinue their use at least 2 weeks prior to protocol initiation
Any other condition that would, in the opinion of the investigator, place them at an unacceptable risk or render them unable to meet the requirements of the protocol.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Lancaster?

Yes, this clinical trial (NCT05835037) has an active research site in Lancaster, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Prediabetic State Treatment Options in Lancaster, PA

If you're searching for prediabetic state treatment options in Lancaster, PA, this clinical trial (NCT05835037) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Lancaster research site is actively enrolling participants for this clinical trial. You'll receive care from experienced prediabetic state specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all prediabetic state clinical trials near you to find additional studies recruiting in your area.

More Essential Tremor Trials in Lancaster, PA

See all essential tremor clinical trials recruiting in Lancaster — not just this study.

Browse Essential Tremor Trials in Lancaster

Ready to Join in Lancaster?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Lancaster, PA